Theme: Current and Future Global Drug Market Trends and Manufacturing

Generic Pharma 2016

Renowned Speakers

Generic Pharma 2016

Conference Series LLC invites all the participants from all over the world to attend  “International Conference and Expo on Generic Drug Market and Contract Manufacturing’’ (Generic Pharma 2016) slated on Nov 07-09, 2016 at Barcelona, Spain, which covers on all aspects of the pharmaceutical sciences, manufacturing, quality with strong emphasis on originality and scientific quality

Generic Pharma 2016 is the largest conference gathering of the global generic industry, attracting attendees from around the globe. This Platform provides a unique forum for generic pharmaceutical executives from around the world to network and hear world-renowned experts discussing the latest insight into the international commercial, legal, and regulatory developments concerning the generic pharmaceutical sector. Generic Pharma 2016 is the most established and leading generic strategy conference in Europe. It unites senior executives from the generic and biosimilar industry to provide fresh insights, future market trends, innovative commercial strategies and opportunities for growth for affordable medicines. This includes Generic Medicines quality and performance characteristics, and intended use of generics and biosimilars It has also been defined as a term referring to any Discovery & Designing A generic drug and  OTCDrugs is the same as a brand-name drug in: dosage, safety, strength, quality, the way it works A drug company develops new drugs & medication as brand-name drugs under patent protection where there is no medication error are to be found. Conference Series LLC Organizes 1000+ Conferences Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access Journals which contains over 30000 eminent personalities, reputed scientists as editorial board members. To know more about the conference series visit: http://conferenceseries.com/

Track 1& 2Global Generic TrendsGeneric DrugsOffice of Generic Drugs (OGD)

A generic drug (generic drugs, short: generics medicines ) is a drug defined as "a drug product that is comparable to a brand/reference listed drug product in dosage form, strength, quality and performance characteristics, and intended use. It has also been defined as a term referring to any drugs marketed under its chemical name without advertising or to the chemical makeup of a drug rather than to the advertised brand name under which the drug is sold. Although they may not be associated with a particular company, generic drugs are subject to the regulations of the governments of countries where they are dispensed. Global generic are labelled with the name of the manufacturer and the adopted name (non-proprietary name) of the drug. A generic drug and OTC Drugs must contain the same active ingredients as the original formulation.

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain; 6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA; Conference on Pharma Marketing November 10-11,2016 at Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto,Canada;2nd Global Pharmaceutical Industry Summit August 22-24, 2016 at  Vienna, Austria; Generic Pharmaceutical Association Annual Meeting  February 13-15, 2017 at Orlando, USA; 6th Regulatory and Scientific Affairs Conference January 26-27 2017 at London UK; 5th Annual Biosimilar Medicines Conference March 23-24 2017 at London UK; 5th Annual Biosimilars and Biomarkers Congress 2017 April 11-12 2017 at London,UK; Generic Pharmaceutical Association (GPhA); Canadian Generic Pharmaceutical Association(CGPA); Southern African Generic Medicines Association; The Danish Generic Medicines Industry Association; European Generic Medicines Association

Track 3: Generic Pills and Generic Medication

generic medicine is a drug that is exactly the same as the brand-name drug, but can only be produced after the brand-name drug's patent has expired. A generic drug and OTC Drugs  is the same as a brand-name drug in:

  • dosage
  • safety
  • strength
  • quality
  • the way it works
  • the way it is taken
  • the way it should be used

A drug company develops new drugs & medication as brand-name drugs under patent protection where there is no medication error are to be found. This in turn protects the investment in the drug's development by giving the drug company the sole right to manufacture and sell the brand-name drug while the patent is in effect.

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain;   6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA; Conference on Pharma Marketing November 10-11, 2016  at Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto, Canada; 2nd Global Pharmaceutical Industry Summit August 22-24, 2016 at Vienna, Austria; Generic Pharmaceutical Association Annual Meeting  February 13- 15, 2017  at Orlando, Florida; 6th Regulatory and Scientific Affairs Conference January 26-27 2017 at London UK; 5th Annual Biosimilar Medicines Conference  March 23-24 2017 at London UK; 5thAnnual Biosimilars & Biomarkers Congress 2017 April 11-12, 2017 at London, UK. France Generic Medicines Association; Association of Innovative Pharmaceutical Manufacturers; Portuguese Generic Medicines Association; Association of the Dutch Generic Medicines Industry; The British Generic Manufacturers Association

Track 4Biosimilars

Biosimilars the generic version of biological is the new buzz word in pharmaceutical industry. Biosimilars are highly similar to licensed reference product not withstanding minor differences in clinically inactive components; also there are no clinically meaningful differences between the biological and the reference product in terms of safety, purity, and potency. This track includes: Licensing of Biosimilars, Biomarkers regulation, Patent issues, BLA filing for Biosimilars, Regulatory prospects of BRIC countries, a paradigm of traditional generics to Biosimilars, Bio waiver approval for Biosimilars and other aspects of Biosimilar approvals.

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain; 6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA; Conference on Pharma Marketing November 10-11, 2016 at Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto, Canada; 2nd Global Pharmaceutical Industry Summit August 22-24, 2016 at Vienna, Austria; Generic Pharmaceutical Association Annual Meeting  February 13-15, 2017 at Orlando, USA; 6th Regulatory and Scientific Affairs Conference January 26-27, 2017, at London UK; 5th Annual Biosimilar Medicines Conference  March 23-24 2017 at London UK; 5thAnnual Biosimilars & Biomarkers Congress April 11-12, 2017 at  London,UK;Generic Pharmaceutical Manufacturers Association; International Generic Pharmaceutical Alliance; European Association of generic drugs; Canadian Association of generic drugs; Japan Association of generic drugs

Track 5Drug Discovery & Designing

Drug design, sometimes referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule and biosimilar such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, Pharmaceutical drug design involves the Drug interactions  of molecules that are complementary in shape and charge to the bimolecular target with which they interact and therefore will bind to it. Molecular Drug design frequently but not necessarily relies on computer modelling technique. Drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered through identifying the active ingredient from traditional remedies or by serendipitous discovery.

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain; 6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA; Conference on Pharma Marketing November 10-11, 2016 at  Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto, Canada ;2nd Global Pharmaceutical Industry Summit August 22-24, 2016 at Vienna, Austria; Generic Pharmaceutical Association Annual Meeting February 13-15, 2017 at Orlando, USA; 6th Regulatory and Scientific Affairs Conference 26-27 January 2017 at London UK; 5th Annual Biosimilar Medicines Conference  March 23-24 2017 at London UK; 2017 ; 9th International Conference on Drug Discovery and Designing February 2-3, 2017 at Melbourne, Australia ; 2nd World Congress & Expo on  Pharmaceutics & Drug Delivery Systems  March 27-29, 2017 at Kuala Lumpur, Malaysia; Drug Design & Medicinal Chemistry Conference September 12-13 2016 at  Boston United States; Generic Pharmaceutical Association (GPhA); Canadian Generic Pharmaceutical Association(CGPA); Southern African Generic Medicines Association; The Danish Generic Medicines Industry Association; European Generic Medicines Association

Track 6Preformulation Studies

Preformulation may be described as a phase of the research and development process where the Preformulation scientist characterizes the physical, chemical and mechanical properties of a new drug substance, in order to develop stable, safe and effective dosage form. The Preformulation studies investigations confirm that there are no significant barriers to the compound’s development as a Marketed Drug /Generic drug. The formulation scientist uses this information to develop dosage forms. Preformulation is a multidisciplinary Drug development. These Preformulation Studies involve bulk characterization, Solubility analysis, Drug Design Analysis.

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain; 6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA ; Conference on Pharma Marketing November 10-11, 2016 at Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto, Canada; 2ndGlobal Pharmaceutical Industry Summit August 22-24, 2016 at Vienna, Austria; Generic Pharmaceutical Association Annual Meeting February 13-15, 2017 at Orlando, USA; 6th Regulatory and Scientific Affairs Conference January26-27 2017 at London; UK; 5th Annual Biosimilar Medicines Conference  March 23-24 2017 at London UK; 2017; 9th Conference on Drug Discovery and Designing February 2-3, 2017 at Melbourne, Australia; 2nd World Congress & Expo on  Pharmaceutics & Drug Delivery Systems March 27-29, 2017 at Kuala Lumpur, Malaysia; Drug Design & Medicinal Chemistry Conference September 12-13 2016 at Boston, United States; France Generic Medicines Association; Association of Innovative Pharmaceutical Manufacturers; Portuguese Generic Medicines Association; Association of the Dutch Generic Medicines Industry; The British Generic Manufacturers Association

Track 5: Advances in Contract Manufacturing

contract manufacturer ("CM") is a manufacturer that contracts with a firm for components or products. It is a form of outsourcing. In the food business a contract manufacturer is called copacker. In a contract manufacturing business model, the hiring firm approaches the contract manufacturer with a design or formula. The contract manufacturer will quote the parts based on processes, labour, tooling, and material costs. Typically a hiring firm will request quotes from multiple CMs. After the bidding process is complete, the hiring firm will select a source, and then, for the agreed-upon price, the CM acts as the hiring firm's factory, producing and shipping units of the design on behalf of the hiring firm. There are many benefits as well as risks to contract manufacturing. Companies are finding many reasons why they should be outsourcing their production to other companies. However, production outside of the company does come with many risks attached.

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain; 6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA; Conference on Pharma Marketing at November 10-11, 2016 Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto, Canada; 2nd Global Pharmaceutical Industry Summit August 22-24, 2016 at Vienna, Austria; Generic Pharmaceutical Association Annual Meeting  February 13-15, 2017 at Orlando, USA; 6th Regulatory and Scientific Affairs Conference January 26-27 2017,at  London UK; 5th Annual Biosimilar Medicines Conference March 23-24 2017 at London UK; 5th Annual Biosimilars & Biomarkers Congress 2017 April 11-12 2017 at London,UK; Generic Pharmaceutical Association (GPhA) ;Canadian Generic Pharmaceutical Association(CGPA); Southern African Generic Medicines Association; The Danish Generic Medicines Industry Association; European Generic Medicines Association

Track 7Interactive and Electronic Contract Manufacturing

Interactive contract manufacturing (ICM) is a neologism to describe the business model of companies that design, build, and deliver interactive assets for their business partners. In this model, advertising agencies team with an ICM in order to provide their clients with websites, interactive campaigns and promotions, and other business solutions using internet technologies. The ICM operates as a complete suite of interactive resources and knowledge for the agency, Deliver interactive assets for their business partners focused on mutually growing revenues. During this process, the ICM traditionally operates behind the scenes and does not have direct contact with the agency's client. Contract manufacturing as a business model has proven tremendously successful, as demonstrated in other industries such as automotive, electronics, textiles, and many others. The ICM serves to maximize business opportunities, economies of scale, and profitability for their partners.

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain; 6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA ; International Conference on Pharma Marketing November 10-11, 2016 at Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto, Canada; 2nd Global Pharmaceutical Industry Summit August 22-24, 2016 at Vienna, Austria; Generic Pharmaceutical Association Annual Meeting February 13-15, 2017 at Orlando, USA; 6th Regulatory and Scientific Affairs Conference January 26-27 2017 at London UK; 5th Annual Biosimilar Medicines Conference  March 23-24 2017 at  London UK; 5thAnnual Biosimilars & Biomarkers Congress 2017 April 11-12 2017 at London,UK; France Generic Medicines Association; Association of Innovative Pharmaceutical Manufacturers; Portuguese Generic Medicines Association; Association of the Dutch Generic Medicines Industry; The British Generic Manufacturers Association

Track 8GMP, GCP and Quality Control

Good Manufacturing Practice is that part of quality management which ensures that products are consistently produced and controlled according to the quality standards appropriate to their intended use and as required by the marketing authorization, clinical trial authorization or product specification. Good Manufacturing practices conference aims at both production and QC. Fact about Current Good Manufacturing Practices (cGMP) is aimed primarily at managing and minimizing the risks inherent in pharmaceutical manufacture to ensure the quality, safety and efficacy of products. FDA regulates the quality of pharmaceuticals very carefully. Current Trends in the FDA is the main regulatory standard for ensuring pharmaceutical quality.

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain; 6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA; Conference on Pharma Marketing November 10-11, 2016 at Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto, Canada; 2nd Global Pharmaceutical Industry Summit August 22-24, 2016 at Vienna, Austria; Generic Pharmaceutical Association Annual Meeting February 13-15, 2017 at Orlando, Florida; 6th Regulatory and Scientific Affairs Conference January 26-27, 2017 at London UK; 5th Annual Biosimilar Medicines Conference March 23-24 2017, at  London; 5th Annual Biosimilars & Biomarkers Congress April 11-12 2017 at London,UK; Generic Pharmaceutical Association (GPhA); Canadian Generic Pharmaceutical Association(CGPA); Southern African Generic Medicines Association; The Danish Generic Medicines Industry Association; European Generic Medicines Association

Track 9Regulatory Affairs and IPR

Regulatory affairs is a comparatively new profession which developed from the desire of governments to protect public health by controlling the safety and efficacy of products in areas including pharmaceuticals, veterinary medicines, medical devices, pesticides, agrochemicals, cosmetics and complementary medicines. Regulatory Affairs is involved in the development of new medicinal products from early on, by integrating regulatory principles and by preparing and submitting the relevant regulatory dossiers to health authorities. Regulatory Affairs is actively involved in every stage of development of a new medicine and in the post-marketing activities with authorised medicinal products. The Regulatory Affairs department is an important part of the organisational structure of Pharmaceutical Industry . Internally it liaises at the interphase of drug development manufacturing, marketing and clinical research. Externally it is the key interface between the company and the regulatory authorities. 

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain;  6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA ; Conference on Pharma Marketing November 10-11, 2016 at  Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto,Canada ;2nd Global Pharmaceutical Industry Summit August 22-24, 2016 at Vienna, Austria; Generic Pharmaceutical Association Annual Meeting February 13  - 15, 2017 Orlando, Florida; 6th Regulatory and Scientific Affairs Conference 26-27 January 2017, London; 5th Annual Biosimilar Medicines Conference March 23-24 2017 at London UK; 3rd World Pharma Conferences October 31-November 2, 2016 at USA; 15th EGA Regulatory and Scientific Affairs Conference January 28-29 2016 at UK; 2ndThe Biomarker Conference  Feb 18-19, 2016 at USA;  ICPRA 2016 18th Conference on Pharmaceutical Regulatory Affairs January 28-29 2016 at Italy. France Generic Medicines Association; Association of Innovative Pharmaceutical Manufacturers; Portuguese Generic Medicines Association; Association of the Dutch Generic Medicines Industry; The British Generic Manufacturers Association

Track 10Generic Drug Market

Generic drug must contain the same active ingredients as the original formulation. According to the U.S. Food and Drug Administration (FDA), generic drugs are identical or within an acceptable bioequivalent range to the brand-name counterpart with respect to Pharmacoepidemiological Studies. By extension, therefore, generics are considered (by the FDA) identical in dose, strength, route of administration, safety, efficacy, and intended use The FDA's use of the word "identical" is very much a legal interpretation, and is not literal. In most cases, generic products are available once the patent protections afforded to the original developer have expired. Generic drugs are in general less effective than the original formulation due to a weaker placebo effect and a stronger placebo effect. When generic products become available, the market competition often leads to substantially lower prices for both the original brand name product and the generic forms. The time it takes a generic drug to appear on the market varies. In most countries of the world, patents give 20 years of protection. However, many countries/regions, e.g. the European Union and the USA may grant up to 5 years of additional protection for drugs ("patent term restoration") if manufactures meet specific goals such as conducting clinical studies for paediatric patients. Manufacturers, wholesalers, insurers, and drugstores can each increase prices at various stages of production and distribution and Drug design reports.

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain;   6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA; Conference on Pharma Marketing November 10-11, 2016 at Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto,Canada:2nd Global Pharmaceutical Industry Summit August 22-24, 2016 at Vienna, Austria; Generic Pharmaceutical Association Annual Meeting  February 13-15, 2017 at Orlando, Florida; 6th Regulatory and Scientific Affairs Conference January 26-27 2017, at London UK; 5th Annual Biosimilar Medicines Conference March 23-24 2017, at London UK; 5thAnnual Biosimilars & Biomarkers Congress 2017 April 11-12 2017 at London,UK,France Generic Medicines Association; Association of Innovative Pharmaceutical Manufacturers; Portuguese Generic Medicines Association; Association of the Dutch Generic Medicines Industry; The British Generic Manufacturers Association

Track 11Contracted drug production

Contract Development and Manufacturing Organization' ('CDMO'), 'sometimes called a' Contract Manufacturing Organization' ('CMO'), is an organization that serves the pharmaceutical industry and provides clients with comprehensive services from drug development through manufacture .Services offered by CDMOs include, but are not limited to: pre-formulation, formulation development, stability studies, method development, pre-clinical and Phase I clinical trial materials,  Outsourced drug producing late-stage clinical trial materials, formal stability, scale-up, registration batches and commercial production. Outsourcing to a CDMO allows the pharmaceutical client to expand its technical resources without increased overhead. The client can then manage its internal resources and costs by focusing on core competencies and high-value projects while reducing or not adding infrastructure or technical staff.

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain; 6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA; Conference on Pharma Marketing November 10-11, 2016 at Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto, Canada; 2nd Global Pharmaceutical Industry Summit August 22-24, 2016 at Vienna, Austria; Generic Pharmaceutical Association  Annual Meeting  February 13 -15, 2017 at Orlando, Florida; 6th Regulatory and Scientific Affairs Conference January 26-27 2017, at London UK; 5th Annual Biosimilar Medicines Conference  March 23-24 2017, at London UK ; 2017 GPHA Annual Meeting February 13-15, 2017 at Orlando, USA; 5thAnnual Biosimilars & Biomarkers Congress April 11-12 2017 at London, UK; France Generic Medicines Association; Association of Innovative Pharmaceutical Manufacturers; Portuguese Generic Medicines Association; Association of the Dutch Generic Medicines Industry; The British Generic Manufacturers Association

Track 12Generic Drug Marketing strategy

The "Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs and Analysis of key therapeutic areas and leading generic drugs  pufecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future road map, Following key trends, market drivers, challenges, Analysis of key therapeutic areas and leading generic trends ,value chain, ecosystem player profiles and strategies and  Regulatory landscape of global trends throughout the globe The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain; 6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA; Conference on Pharma Marketing November 10-11, 2016 at Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto, Canada; 2nd Global Pharmaceutical Industry Summit August 22-24, 2016 at Vienna, Austria; Generic Pharmaceutical Association  Annual Meeting February 13 -15, 2017 at Orlando, USA; 6th Regulatory and Scientific Affairs Conference 26-27 January 2017, at London UK; 5th Annual Biosimilar Medicines Conference March 23-24 2017 at London UK;  2017 GPHA Annual Meeting February 13-15, 2017 at Orlando, USA; 5th Annual Biosimilars & Biomarkers Congress 2017 April 11-12 2017 at London, UK; Generic Pharmaceutical Manufacturers Association; Generic Pharmaceutical Alliance; European Association of generic drugs; Canadian Association of generic drugs; Japan Association of generic drugs

Track 13: Integrated Supply Chain Management and Logistics

Supply chain management (SCM) is the oversight of materials, information, and finances as they move in a process from supplier to manufacturer to wholesaler to retailer to consumer. Supply chain management involves coordinating and integrating these flows both within and among companies. Logistics is the term widely used in business for the range of activities associated with the movement, storage and handling of materials. The management of logistics has been revolutionised over the past 30 years and has come to be regarded as a key determinant of business competitiveness. Companies have substantially improved their performance not only by overhauling their internal logistics, but also by managing more effectively their external links with suppliers. This has become known as supply chain management. These developments have created a healthy demand for well-qualified logistics and supply chain managers in most sectors of the economy.

Relevant Conferences:

5th European Biosimilars Congress June 27-29, 2016 at Valencia, Spain; 6th Pharmaceutical Regulatory Affairs Conference Sep 29- Oct 01, 2016  at Orlando, USA; Conference on Pharma Marketing November 10-11, 2016 at Alicante, Spain; 5th Summit on GMP, GCP and Quality Control, August 12-13, 2016 at Toronto, Canada; 2nd Global Pharmaceutical Industry Summit August 22-24, 2016 at Vienna, Austria; Generic Pharmaceutical Association Annual Meeting February 13  - 15, 2017 at Orlando, Florida; 6th Regulatory and Scientific Affairs Conference January 26-27 2017, at London UK; 5th Annual Biosimilar Medicines Conference 23-24 March 2017 at  London UK;  2017 GPHA Annual Meeting February 13 - 15, 2017 at Orlando, USA; 5thAnnual Biosimilars & Biomarkers Congress 2017 April 11-12 2017 at  London, UK Generic Pharmaceutical Association (GPhA) ; Canadian Generic Pharmaceutical Association(CGPA); Southern African Generic Medicines Association; The Danish Generic Medicines Industry Association; European Generic Medicines Association

Conference Series LLC invites all the participants from all over the world to attend  “International Conference and Expo on Generic Drug Market and Contract Manufacturing’’ (Generic Pharma 2016) slated on Nov 07-09, 2016 at Barcelona, Spain,which covers on all aspects of the pharmaceutical sciences, manufacturing, quality with strong emphasis on originality and scientific quality

Conference Series LLC  is a renowned organization that organizes highly notable pharmaceutical conferences throughout the globe.

Conference Series LLC organizes 600+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contain over 70000 eminent personalities, reputed scientists as editorial board members, 1200 Symposium & Workshops and 5 million followers. To know more about the conference series visit: http://conferenceseries.com/. To its credit Conference Series LLC invites all the participants across the globe to attend the "International Conference and Expo on Generic Drug Market and Contract Manufacturing’’.

Generic Pharma 2016 conveys recent developments in Generic drug marketing and production of generic drugs and contract manufacturing. A complete knowledge of a scientific discipline that described the effects of generic drug marketing and generic Pharma now explores the Scope of generic drug marketing in industry. Generic Pharma 2016 provides detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified and sales forecasts by product categories and major country markets these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the generic drug market. The wider economic environment is also taken into account.

The scope of Generic Pharma discusses the implications of all the above-mentioned trends, in the context of the current size and growth of the generics market, both in global terms and analysed by the most important national markets. The nature and structure of the generics industry is discussed, and an update on M&A activity. With first-generation biopharmaceutical products reaching the end of their patent lives, a whole new market field—bio generics or bio similar is opening up, for those generics companies capable of (or prepared to buy-in) the technological expertise required. The international landscape is changing for generics as for all pharmaceuticals. China, India, Eastern European countries and Brazil are among rising centres of generic activity.

Title: International Conference and Expo on Generic Drug Market & Contract Manufacturing

Dates & Venue: Nov 07-07 2016 at  Barcelona, Spain

Theme: Current and Future Global Drug Market Trends and Manufacturing

Generic Pharma 2016 conveys recent developments in

A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.

Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs.

The "Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years.As the market consolidates; larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan.

In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs.

Driven by the cost saving potential of Biosimilars drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved Biosimilars drugs will account for more than $20 Billion in revenue by the end of 2020.

Scope and Importance:-

After the expiry of patent or marketing rights of the patented drug, generic drugs are marketed. Generic drugs are available at affordable prices with maintaining quality. These ‘Generic formulations balance public interest as critical disease like cancer, AIDS etc. It is widely accepted both developed and developing countries. An estimated half of all prescriptions in the USA are now filed with approved generic drugs. In order to market drugs, U.S. generic manufacturers must have a permit and approval from the Food and Drug Administration (FDA) indicating that the active ingredient is approximately the same as that of the brand name. The determination of drug approval is made according to whether it is pharmaceutically equivalent, bio-available, and bioequivalent. World Health Organization (WHO) provided a definition for counterfeit drugs.

About Venue:

Barcelona is the capital city of the autonomous community of Catalonia in Spain and Spain's second most populated city, with a population of 1.6 million within its administrative limits. Its urban area extends beyond the administrative city limits with a population of around 5 million people, being the sixth-most populous urban area in the European Union after Paris, London, Madrid, the Ruhr area, and Milan. It is the largest metropolis on the Mediterranean Sea, located on the coast between the mouths of the rivers Llobregat and Besòs, and bounded to the west by the Serra de Collserola mountain range, the tallest peak of which is 512 metres (1,680 ft.) high. Founded as a Roman city, in the Middle Ages Barcelona became the capital of the County of Barcelona. After merging with the Kingdom of Aragon, Barcelona continued to be an important city in the Crown of Aragon as an economical and administrative centre of this Crown and the capital of the Principality of Catalonia. 

Societies Associated with Generic Pharma:

  • Canadian Generic Pharmaceutical Association (CGPA)
  • International Generic Pharmaceutical Alliance - IGPA
  • European Generic medicines Association
  • Generic Pharmaceutical Association - FiercePharma
  • British Generic Manufacturers Association
  • Worldwide Pharmaceutical Association -
  • Generic Pharmaceutical Association (GPhA )

Country wise Statistics (European):

  • European Association of Faculties of Pharmacy (EAFP)
  • European Association for Health Information and Libraries (EAHIL)
  • European Association of Hospital Pharmacists (EAHP)
  • European Biosafety Association (EBSA)
  • European Federation for Medicinal Chemistry (EFMC)
  • European Federation for Pharmaceutical Sciences (EUFEPS)
  • European Pharmaceutical Students Association (EPSA)
  • European Society of Clinical Pharmacy (ESCP)
  • European Society of Regulatory Affairs (ESRA)
  • Pharmaceutical Group of the European Union (PGEU)

Worldwide Statistics (International):

  •     Association de Pharmacie Galénique Industrielle (APGI)
  •     Controlled Release Society (CRS)
  •     Institute of Pharmacy Management International (IPMI)
  •     International Academy of Compounding Pharmacists (IACP)
  •     International Association for Pharmaceutical Technology (APV)
  •     International health Association
  •     International Federation of Pharmaceutical Manufacturers Associations (IFPMA)
  •     International Federation of Pharmaceutical Wholesalers (IFPW)
  •     International Pharmaceutical Excipients Council (IPEC)
  •     International Pharmaceutical Federation (FIP)
  •     International Pharmaceutical Students Federation (IPSF)
  •     International Society for Medical Publication Professionals (ISMPP)
  •     International Society of Oncology Pharmacy Practitioners (ISOPP)
  •     International Society for Pharmaceutical Engineering (ISPE)
  •     International Society for Pharmacoepidemiology (ISPE)
  •     International Society for the History of Pharmacy (ISHP)
  •     International Society for the Study of Xenobiotics (ISSX)
  •     International Society of Pharmaceutical Compounding (ISPhC)
  •     International Young Pharmacists' Group (YPG)
  •     Parenteral Drug Association (PDA)
  •     Regulatory Affairs Professionals Society (RAPS)
  •     Society for Biomolecular Sciences (SBA)
  •     Society for Cell Science (SFCS)
  •     Society for Translational Oncology (STO)

Statistical Representation:

 

               

 

Industries Associated with Pharmaceutical Research:

A. City statistics:

 List of Pharmaceutical companies in Spain:

  • Almirall
  • Cinfa Laboratories
  • Curaxys                  
  • Esteve
  • Grifols
  • Inibsa
  • SOM Biotech
  • Zeltia

      Country Statistics:

 

Worldwide Statistics:

Pharmaceutical Companies Worldwide

Abbott Laboratories

Almirall

AbbVie

Alphapharm

Acadia Pharmaceuticals

Altana Pharma AG

Actavis

Amgen

Actelion

Amico Laboratories

Advaxis

Anavex Life Sciences

Ajanta Pharma

Apotex Inc.

Alcon

Astellas Pharma

Alexion Pharmaceuticals

AstraZeneca

Alkaloid

Avax Technologies

Alkermes

Avella Specialty Pharmacy

Allergan

Axcan Pharma

Alliance Boots

Aurobindo Pharma

Bargn Farmaceutici Phils Co

Cadila Healthcare

Barr

Celgene

Basi

Cephalon

Bausch & Lomb

Chiesi Farmaceutici S.p.A.

Baxter International

Chugai Pharmaceutical Co.

Bayer Schering Pharma AG

CinnaGen

Beximco Pharmaceuticals Ltd

Cipla

Bial

CoCo Therapeutics

Biocon

Covance

Biogen Idec

Crucell

Biolex

CSL Limited

Bionovo

Daiichi Sankyo

Biotecnol

Dainippon Sumitomo Pharma

Biovail

Dawakhana Shifaul Amraz

Biovitrum

Debiopharm

Bluepharma

Diabetology Ltd

Boehringer-Ingelheim

Diffusion Pharmaceuticals

Bosnalijek

Dr. Reddy's Laboratories

Bristol-Myers Squibb

 

Ego Pharmaceuticals

Help Remedies

Eisai (company)

Hetero Drugs

Elder Pharmaceuticals

Hexal Australia

Eli Lilly and Company

Hikma Pharmaceuticals

Elorac, Inc.

Hoffmann–La Roche

Emergent BioSolutions

Hovione

Endo Pharmaceuticals

Ipca Laboratories

Eskayef Bangladesh Limited

Incepta Pharmaceuticals

F. Hoffmann–La Roche Ltd., which owns Genentech and Chugai Pharmaceuticals

Institute for OneWorld Health

Ferring Pharmaceuticals

Intas Biopharmaceuticals

Fresenius Kabi

Intercytex

Fresenius Medical Care

Interphil Laboratories

Galderma Laboratories

Janssen Pharmaceutica Products, a subsidiary of Johnson & Johnson

Getz Pharma

Jenapharm, a subsidiary of Bayer Schering Pharma

Gilead Sciences

JN-International Medical Corporation

GlaxoSmithKline

Johnson & Johnson

Glenmark Pharmaceuticals

Julphar

GPC Biotech

Lupin Limited

Grifols

Menarini

Gulf Pharmaceutical Industries (Julphar)

Merck & Co.

3M Pharmaceuticals

Merck KGaA

MannKind Corporation

Mitsubishi Pharma

McGuff

Mylan

Medinfar

Novartis

Melior Discovery

Novo Nordisk

NovaBay Pharmaceuticals

Noxxon

Octapharma

Ortho-McNeil Pharmaceutical, a subsidiary of Johnson & Johnson

Orexo

Otsuka Pharmaceutical Co.

Orion Pharma

Pharmacosmos

Panacea Biotec Ltd

Pierre Fabre Group

Par Pharmaceutical

Piramal Healthcare

Patheon

Pliva

Perrigo

Procter & Gamble

Pfizer

Purdue Pharma

Pharma Medica

Renovo

Pharma Nord

Respa Pharmaceuticals

Gedeon Richter Ltd.

Rubicon Research

Ranbaxy Laboratories, generics arm of Daiichi Sankyo

Reckitt Benckiser

Regeneron Pharmaceuticals

Solvay Group

Salix Pharmaceuticals

Square Pharmaceuticals

Sanofi

STADA Arzneimittel

Sunovion

Strides Arcolab

Serum Institute of India

Sun Pharmaceutical

Servier Laboratories

Takeda Pharmaceutical Co.

Shionogi

Tasly

Shire plc

Teva Pharmaceuticals

Sigma Pharmaceuticals

Torrent Pharmaceuticals

Sinopharm Group

Vertex Pharmaceuticals

UCB

Vion Pharmaceuticals, Inc.

Unichem Laboratories

Wallace Pharmaceuticals

UNILAB, also known as United Laboratories

Wockhardt

Valeant Pharmaceuticals International, formerly ICN Pharmaceuticals

Yuhan Corporation

VAV Life Sciences

Zandu Pharmaceuticals

Veloxis Pharmaceuticals

Zentiva

 
Statistical Representation:

Market Value on Pharmaceutical Research:

Country Statistics:

This statistic depicts the global leading generics manufacturers' revenues in 2014-2015. In that year, Teva's generic division reported some 9.1 billion U.S. dollars of revenue worldwide. Thus, Pharmaxecil is the world's leading generic manufacturer.

Worldwide Statistics:

Top 20 pharmaceutical companies based on worldwide prescription drug revenues in 2014 (in million U.S. dollars)

The top pharmaceutical companies in the world are Novartis, Pfizer, and Sanofi, based on 2014 pharmaceutical revenues. The companies generated 51.3 billion U.S. dollars, 44.9 billion U.S. dollars, and 40 billion U.S. dollars, respectively, in the year 2014.

Pharmaceutical companies are best known for manufacturing pharmaceutical drugs. These drugs have the aim to diagnose, to cure, to treat, or to prevent diseases. The pharmaceutical sector represents a huge industry, with the global pharmaceutical market being worth nearly one trillion U.S. dollars. The best known top global pharmaceutical players are Pfizer, Merck and Johnson & Johnson from the U.S., Novartis and Roche from Switzerland, Sanofi from France, etc. Most of these companies are involved not only in pure pharmaceutical business, but also manufacture medical technology and consumer health products, vaccines, etc. For example, Johnson & Johnson makes most of its revenues through medical devices, diagnostics and consumer health products.

Market Growth of Pharmaceutical Research in the last and upcoming ten years

Pharmaceuticals are one of the world's most profitable industries. During the last 30 years, the industry has spent billions of dollars on research and reaped billions in return. In 2008 alone, the pharmaceutical industry sold $773 billion in products worldwide-a number that has consistently grown for the past 8 years and is projected to increase again by 2.5 to 3.5 percent in 2017, according to the drug market research firm IMS Health.

But the process that turns research dollars into medicines is a slow and often arduous one. It now takes an average of 12 to 15 years and up to $1.7 billion for a drug to go from discovery to market, according to The Pharmaceutical Research and Manufacturers of America. And despite all the time and money invested, only a handful of drugs are approved by the FDA each year.

The arduous drug approval process reveals a central fact about Big Pharma: it's one of the most intensely regulated industries in the world. The U.S. Food and Drug Administration (FDA) and its European Union counterpart, the European Medicines Agency (EMEA), govern every aspect of a drug's development-from chemicals used in the drug and clinical study instructions, called protocols, to packaging components and marketing materials. This strict oversight is meant to protect patient safety, and pharma companies take regulatory oversight seriously. The constant pressure to adhere to government mandates shapes every aspect of a pharma firm's organization, operations, and culture. For example, drug companies maintain powerful regulatory affairs divisions-the departments that deal with government agencies-and they tend to be risk-averse.

Country Statistics:-

  • Growth in the EU5 is expected in the -1 to 2% range through 2016 compared to 3.8% for 2007-11, as national debt incurred due to the global economic crisis will be addressed through austerity programs and healthcare cost containment.
  • Limited savings from patent expires in the forecast period are prompting policy shifts to encourage greater use of generics and lower reimbursement, particularly in Spain.
  • Policies to examine the value newer medicines bring, when assessing their reimbursement prices, are being adopted in the UK with “value-based pricing” and in Germany with assessments under the AMNOG program.
  • Governments will take direct actions to control spending growth, or in some cases make real reductions, particularly in hospital spending.

Products manufactured by the industry relating to Pharmaceutical Research:

     

In our new study you find analytical profiles of top companies worldwide. There you analyse historical data, market shares, revenue forecasts, and growth rates. Discover qualitative analysis too.

The following sections highlight what you find in our new investigation.

Assessments of top companies - activities, results, competition, and potential sales

Our report analyses 50 manufacturers of generic medicines. In general a company profile     gives you the following information:

  • Discussion of a company's activities, outlook, and recent financial results
  • Assessment of its developments - mergers and acquisitions (M&A), new products, and collaborations, Inc. alliances, partnerships and joint ventures
  • Forecasting of generic drug revenues to 2023 (for 20 of the companies).

Big pharma - generics production by the pharma industry's largest companies

First, our study gives you discussions, financial analyses, and commercial outlooks for five generic drug producers among the world's leading pharmaceutical companies:

  • Teva Pharmaceutical Industries
  • Novartis (Sandoz)
  • Abbott Laboratories
  • Pfizer
  • Sanofi.

North America - outlooks for leading generic drug manufacturers

Next, our report analyses 12 North American generics specialists, including these:

  • Mylan
  • Actavis
  • Hospira
  • Par Pharmaceutical
  • Mallinckrodt
  • Apotex
  • Valeant.

Europe - prospects for leading generics players

You also discover outlooks for 11 European generics specialists, including these:

  • Fresenius Kabi
  • Pharmstandard
  • Stada Arzneimittel
  • Gedeon Richter
  • Krka.

India - analysis of leading generic drug firms

Our new work also assesses 10 Indian generic drug producers, including these:

  • Ranbaxy Laboratories
  • Cipla
  • Dr. Reddy's Laboratories
  • LupinAurobindo
  • Wockhardt
  • Sun Pharmaceutical Industries.

Producers from the rest of the world - assess progress and prospects

You also discover outlooks for 12 generic drug makers based in other regions, including these companies:

  • Aspen Pharmacare
  • Laboratorios Roemmers
  • Nichi-Iko
  • Sawai Pharmaceuticals
  • Taro Pharmaceutical Industries
  • Adcock Ingram
  • Eurofarma.

Developing markets such as Japan, Brazil and China will prove important for generic drug sales from 2013 to 2023, our analyses show.

Issues affecting generic drug manufacturing and selling

In addition, our report discusses issues and events affecting that industry and market from 2013, including these:
Specialty generics - difficult-to-produce medicines with high profit margins

  • Super-generics - shift towards innovation, with expanding R&D budgets
  • Mergers and acquisitions influencing that part of healthcare
  • Big pharma firms targeting generics - diversification of portfolios
  • Expansion internationally - targeting emerging national markets
  • Intellectual property (IP) - regulation and opportunity
  • Biosimilars - opportunities for generic and originator companies.

There you explore the generic drug industry's strengths, weaknesses, opportunities, and threats. In particular, the merger of Atavism and Watson forms a notable event. Discover now what the future holds.

Funds allotted to Pharmaceutical Research:

Worldwide:

Pharma companies have traditionally funded their internal R&D efforts totally on their     own by investing 15% or more of their top line revenues to pay for these endeavours’. In addition, in order to tap into R&D going on outside their companies, pharma has financially supported external R&D efforts in deals with small biotech companies, research institutes, and universities. In fact, as funding for agencies like the NIH has stagnated over recent years, pharma has become an important source of funds to support early stage research.

Despite R&D budgets in the billions of dollars, pharma is now seeking to supplement their internal R&D investments with outside funding. One source has been major foundations.  The recent Cystic Fibrosis Foundation investment of $58 million into Pfizer R&D to support new research into areas for this disease is a perfect example. The justification for such deals is that pharma companies have a proven R&D track record for delivering new medicines, and the foundations feel that, by tapping into these scientists, they can maximize their chances for getting breakthrough medications.

Now Pharma has found a new investor for its R&D efforts – the U.S. government. In what is being hailed as the a “first-of-its-kind” collaboration, GlaxoSmithKline (GSK) has entered into a potential $200 million antibiotics pact with the Biomedical Advanced Research and Development Authority (BARDA), a division of Health & Human Services (HHS), to develop drugs to fight antibiotic resistance and bioterrorism. HHS will provide $40 million for the first 18 months of the deal to develop several antibiotics in the GSK portfolio. The work will be monitored by a joint BARDA-GSK committee and, if warranted, the agreement can be renewed with HHS providing additional funding of up to a total of $200 million over 5 years.

Federal Agencies:

  • Grants.gov
  • NIH Grants & Funding
  • USFDA
  • NSF Funding
  • USDA NIFA Grants
  • AHRQ Funding & Grants
  • PCORI Funding
  • DOD Grants
  • DARPA (Defense Advanced Research Projects Agency)

Non-Federal Research Associations and Foundations:

  • Agency for Healthcare Research & Quality (AHRQ)
  • National Pharmaceutical Council

Pharmacy research funding:

  1. Harold and Marjorie Moss Charitable Trust:  This charitable trust awards funds for pharmacy training at undergraduate, postgraduate and doctorate level.
  2. The Leverhulme Trade Charities Trust: The Leverhulme Trade Charities Trust makes grants for the benefit of chemists, commercial travellers and grocers. Pharmacists are able to apply for undergraduate and postgraduate bursaries.
  3. The National Pharmacy Association: The National Pharmacy Association Health Education Foundation offers a bursary intended to support community pharmacists who wish to develop their skills to undertake research relating to community pharmacy practice.
  4. The United Kingdom Clinical Pharmacy Association: The UKCPA offer a number of annual awards for various aspects of clinical practice, patient safety and IT.

Members Associated with Pharmaceutical Research:

In regard to Industrial personnel:

Research Positions:-

Lab technician

Research Associate

Research Scientist

Clinical Development and medical Jobs:

Clinical Research Physician

Clinical Research Associate

Regulatory Affairs Associate

Bio Statistician

Clinical Data Manager

Medical Science Liaison

Manufacturing and Quality Assurance Jobs:

Process Engineer

Quality Control Analyst

Quality Assurance Specialist

Business Operations Jobs:

Market research Analyst

Associate Product Manager

Product Manager

Strategy Director

Business Development Manager

Apart from the industrial personnel where most of the research works is done, other research communities include:

  • Academicians include Student community.
  • Researchers include Post docs, Research Associates.
  • Scientists include Professors, Associate professors, and Assistant professor.
  • Industries include Presidents, CEO’s, and R&D Managers.

Statistical representation:

In summary, then, our new research and analysis give you the following knowledge:

  • Profiles of 50 leading companies - assess product ranges, strategies, and sales results, also gaining revenue forecast to 2023 for 20 organisations
  • Competition and opportunities - see what affects the generics market, learning what shapes its future, esp. prospects for sustaining and developing business.
  • Analysis of what stimulates and restrains the generic medicines industry - discover challenges and strengths, helping you compete and gain advantages
  • Issues affecting established competitors and firms entering the generics sector - explore needs, practices, and outlooks for future success.

 

Pre-Conference Workshop
Title: Advances in Generic Pharmaceuticals and Biosimilars
Venue: Touro College of Pharmacy,  NY 10027, USA
Date: March 29, 2016


”Touro College of Pharmacy is excited to announce a one day symposium to be held on March 29, 2016 that will focus on “Advances in Generic Pharmaceuticals and Biosimilars”. The symposium will be held at the Manhattan Campus of the Touro College of Pharmacy located at 231 West 124th Street. Leading scientists in the pharmaceutical and biotechnology industry as well as in academia will present seminars addressing advances in the development, manufacturing, marketing and regulatory pathways of generics and biosimilars. The Pre-Conference workshop is being sponsored by Conference Series LLC Conferences.

Touro College of Pharmacy, a member of the Touro College and University System, is committed to providing an outstanding education to its students, dedicated service to the profession of pharmacy and advancing the field of pharmacy through research and scholarship.
 

Zvi G. Loewy, Ph.D.,
Professor and Chair
Pharmaceutical and Biomedical Sciences
Immediate Past Dean, Touro College of Pharmacy
230 West 125th Street | Suite 507 | New York, NY 10027 | USA

 

Biosimilars 2015

Conferenceseries.LLC hosted the 4th International Conference and Exhibition on Biologics and Biosimilars at Double Tree by Hilton Hotel Baltimore, USA during October 26-28, 2015.The conference was designed around the theme of “ The future of Next Generation Biologics and Biosimilars”  and was a great success where eminent keynote speakers from various reputed companies made their resplendent presence and addressed the gathering.

Biosimilars 2015 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the field of Biologics and Biosimilars.

Conferenceseries.LLC would like to convey a warm gratitude to all the Honorable guests, Keynote Speakers, Media Partners, Exhibitors and Covance Laboratories as sponsors of Biosimilars 2015:

Patrick Lucy, Pfenex Inc., USA
Kamali Chance, Quintiles Inc., USA
Christopher Leintz, Pfizer, USA

Mark A Emalfarb,  Dyadic Internatrional, USA

Sarfaraz K NIazi, Therapeutic Proteins International, USA

Angela Furlanetto, Dimock Stratton LLP, Canada

Conferenceseries.LLC  on behalf of the conference, congratulates the Best Poster awardees for their outstanding performance and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavours. 

Conferenceseries.LLC also took the privilege of felicitating Biosimilars 2015 Organizing Committee, Keynote Speakers, Chair and Co-Chairs whose support made conference a great success.

With the enormous feedback from the participants and supporters of Biosimilars 2015, Conferenceseries.LLC is glad to announce 5th European Biosimilars Congress during June 27-29, 2016 at Valencia, Spain and 6th International Conference and Exhibition on Biologics and Biosimilars through October 20-22, 2016 at Houston, USA


Past Reports  Proceedings  Gallery  

Pharmaceutica-2014

On March 24-26, 2014, Conference Series LLC at Hilton San Antonio Airport, USA organized its 4thInternational Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems. This conference was Conference Series LLC endeavor to strengthen the future of the Novel Drug delivery Systems with scientists pharmacists, researchers, health care professionals, university professors, industrialists, pharmaceutical associations, editorial board members of CONFERENCE SERIES LLC journals, and students.

The keynote speakers for the conference were: Panayiotis P Constantinides, Biopharmaceutical & Drug Delivery Consulting, USA, Jason Vaughn, Patheon Pharmaceuticals, USA, Tejraj M Aminabhavi, Soniya College of Pharmacy, India,Gjumrakch Aliev, GALLY International Biomedical Research Consulting LLC, USA,Konstantin Tsinman, Pion Inc., USA and Walter Rudzuski, Texas State University, USA.

The keynote sessions, invited lectures by honorable guests, and all the other sessions highlighted the current challenges, issues, opportunities, innovations and ideas, in pharmaceutical research, that was reflected by the theme of the conference “Pre-formulation, Formulation, and Physiology; Approaches for Drug Delivery Systems."  The theme touched upon various topics like Recent Technologies in Novel Drug Delivery Systems, Routes of Drug Administration, Drug Delivery Targeting, Biopharmaceuticals, Current Issues of Pharmaceutics in Global Market, Nanotech for Drug Delivery, Personalized Medicine, Prodrugs and Targeted Drug Delivery, Novel Advances in Drug Delivery to Brain, Drug Delivery Systems and Drug Formulations for Cancer, Pharmacokinetic Considerations of Drug Delivery, and Management of QA/QC in Pharmaceutical Industry. This gave a rewarding learning environment to all the attendees.

Conference Series LLC “Pharmaceutica” is known for uplifting the future of pharmacy by encouraging students and fellow researchers to present their work through poster presentations. Students participated with great zeal and the best posters were awarded for their efforts and outstanding contribution to the pharmacy research. The best poster awardees were: Dorota Watrobska-Swietlikowska, The Medical University of Gdansk.

Conference Series LLC wishes to acknowledge all the organizing committee members, chair and co-chair, editorial board members of Conference Series LLC journals, speakers, students, sponsors, exhibitors and media partners in making this event a great success.

Thank you to everyone for the enormous exquisite response. This inspires us to continue organizing events and conferences for furthering the Pharmaceutical research. Conference Series LLC therefore, is glad to announce its "5th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems" which will be held during March 09-11, 2015 in Dubai.

 


Past Reports  Proceedings  Gallery  

Pharmaceutica-2013

On April 8-10, 2013, Conference Series LLC at Chicago/Northbrook USA organized 3rd International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems. This conference was Conference Series LLC endeavour to strengthen the future of the Pharmacy profession together with pharmacists, researchers, health care professionals, university professors, industrialists, pharmaceutical associations, editorial board members of Conference Series LLC journals, and students.

The keynote speakers for the conference were: Panayiotis P. Constantinides, Biopharmaceutical & Drug Delivery Consulting, USA, Wei-Chiang Shen, University of Southern California, USA, Kevin J. Filipski, Pfizer Worldwide Research & Development, USA, Giancarlo Morelli, University of Naples, Italy, and David J. Brayden, University College Dublin, Ireland.

The keynote sessions, invited lectures by honorable guests, and all the other sessions highlighted the current challenges, issues, opportunities, innovations and ideas, in pharmaceutical research, that was reflected by the theme of the conference “Novel Advances in Pharmaceutical R&D."  The theme touched upon various topics like Recent Technologies in Novel Drug Delivery Systems, Routes of Drug Administration, Drug Delivery Targeting, Biopharmaceuticals, Current Issues of Pharmaceutics in Global Market, Nanotech for Drug Delivery, Personalized Medicine, Prodrugs and Targeted Drug Delivery, Novel Advances in Drug Delivery to Brain, Drug Delivery Systems and Drug Formulations for Cancer, Pharmacokinetic Considerations of Drug Delivery, and Management of QA/QC in Pharmaceutical Industry. This gave a rewarding learning environment to all the attendees.

Conference Series LLC “Pharmaceutica” is known for uplifting the future of pharmacy by encouraging students and fellow researchers to present their work through poster presentations. Students participated with great zeal and the best posters were awarded for their efforts and outstanding contribution to the pharmacy research. The best poster awardees were: Srinath Muppalaneni, Mohsen. A. Bayomi, Povilas Norvaisas, and Padmakanthan Santha Raghu.

Conference Series LLC group wishes to acknowledge all the organizing committee members, chair and co-chair, editorial board members of Conference Series LLC group journals, speakers, students, sponsors, exhibitors and media partners in making this event a great success. 

Thank you everyone for the enormous exquisite response. This inspires us to continue organizing events and conferences for accelerating the Pharmaceutical research. Conference Series LLC therefore, is glad to announce "4th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems" which will be held during March 2014 in San Antonio, USA.

 


Past Reports  Gallery  

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date Nov 07- 09, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2 Day 3
Poster Opportunity Available

Media Partners

Conferenceseries Destinations